Literature DB >> 25782576

Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm.

Jürgen Podlech1, Matthias J Reddehase, Barbara Adler, Niels A W Lemmermann.   

Abstract

Initial virus entry into cells of host organs and subsequent spread of viral progeny between tissue cells are events fundamental to viral pathogenesis. Glycoprotein complexes inserted in the virion envelope are critically involved in the cell entry process. Here we review and discuss recent work that has shed light on the in vivo role of the trimeric glycoprotein complex gH/gL/gO of murine cytomegalovirus (mCMV) as a model to propose the role of the corresponding complex of human CMV, for which experimental studies in vivo are not feasible due to the host species specificity of CMVs and evident ethical constraints. A novel approach combining gO transcomplementation of a genetically gO-deficient virus and a mathematical log-linear regression analysis of the viral multiplication kinetics in host tissues revealed a critical role of mCMV gH/gL/gO only in first target cell entry of virions arriving with the circulation, whereas intra-tissue spread proceeded unaffected also in the absence of gH/gL/gO. These findings predict that targeting gO for an antiviral intervention may be of prophylactic value in preventing the seeding of virus to organs, but will likely fail to interfere with an established primary organ infection or with recurrent infection after virus reactivation from latency within tissue cells. The demonstration in the murine model of alternative gH/gL complexes gH/gL/gO and gH/gL/MCK-2, substituting one another in a redundant fashion for securing viral spread in tissues, has the medically interesting bearing that targeting the gH/gL core complex directly may be a promising approach to preventing primary, established, and recurrent CMV infections.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25782576     DOI: 10.1007/s00430-015-0405-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  53 in total

1.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

3.  Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary Glands due to a fixed mutation of MCK-2.

Authors:  Stefan Jordan; Johannes Krause; Adrian Prager; Maja Mitrovic; Stipan Jonjic; Ulrich H Koszinowski; Barbara Adler
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus.

Authors:  W J Britt; D Auger
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

5.  Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes.

Authors:  Claudio Ciferri; Sumana Chandramouli; Danilo Donnarumma; Pavel A Nikitin; Michael A Cianfrocco; Rachel Gerrein; Adam L Feire; Susan W Barnett; Anders E Lilja; Rino Rappuoli; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

6.  Murine cytomegalovirus CC chemokine homolog MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection.

Authors:  N Saederup; S A Aguirre; T E Sparer; D M Bouley; E S Mocarski
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration.

Authors:  Sarah Straschewski; Marco Patrone; Paul Walther; Andrea Gallina; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

8.  Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B.

Authors:  K A Boyle; T Compton
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues.

Authors:  Nikolaus Wirtz; Sina I Schader; Rafaela Holtappels; Christian O Simon; Niels A W Lemmermann; Matthias J Reddehase; Jürgen Podlech
Journal:  Med Microbiol Immunol       Date:  2008-03-26       Impact factor: 3.402

Review 10.  Avoiding the void: cell-to-cell spread of human viruses.

Authors:  Quentin Sattentau
Journal:  Nat Rev Microbiol       Date:  2008-11       Impact factor: 60.633

View more
  13 in total

1.  Role of PDGF receptor-α during human cytomegalovirus entry into fibroblasts.

Authors:  Kai Wu; Adam Oberstein; Wei Wang; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

Review 2.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

Review 3.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

4.  An endocytic YXXΦ (YRRF) cargo sorting motif in the cytoplasmic tail of murine cytomegalovirus AP2 'adapter adapter' protein m04/gp34 antagonizes virus evasion of natural killer cells.

Authors:  Annette Fink; Franziska Blaum; Marina Babic Cac; Stefan Ebert; Niels A W Lemmermann; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2015-04-08       Impact factor: 3.402

Review 5.  Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.

Authors:  Niels A W Lemmermann; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2016-08-18       Impact factor: 3.402

6.  Bile Acids Act as Soluble Host Restriction Factors Limiting Cytomegalovirus Replication in Hepatocytes.

Authors:  Anna-Kathrin Schupp; Mirko Trilling; Stephanie Rattay; Vu Thuy Khanh Le-Trilling; Katrin Haselow; Jan Stindt; Albert Zimmermann; Dieter Häussinger; Hartmut Hengel; Dirk Graf
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

7.  Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice.

Authors:  Simone Thomas; Sebastian Klobuch; Jürgen Podlech; Bodo Plachter; Petra Hoffmann; Angelique Renzaho; Matthias Theobald; Matthias J Reddehase; Wolfgang Herr; Niels A W Lemmermann
Journal:  PLoS Pathog       Date:  2015-07-16       Impact factor: 6.823

8.  Role of Envelope Glycoprotein Complexes in Cell-Associated Spread of Human Cytomegalovirus.

Authors:  Nina Weiler; Caroline Paal; Kerstin Adams; Christopher Calcaterra; Dina Fischer; Richard James Stanton; Dagmar Stöhr; Kerstin Laib Sampaio; Christian Sinzger
Journal:  Viruses       Date:  2021-04-02       Impact factor: 5.818

9.  Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.

Authors:  Kerstin M Gergely; Jürgen Podlech; Sara Becker; Kirsten Freitag; Steffi Krauter; Nicole Büscher; Rafaela Holtappels; Bodo Plachter; Matthias J Reddehase; Niels A W Lemmermann
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 7.561

10.  Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance.

Authors:  Rafaela Holtappels; Niels A W Lemmermann; Jürgen Podlech; Stefan Ebert; Matthias J Reddehase
Journal:  Front Immunol       Date:  2016-06-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.